We therefore aimed to evaluate the role of macrophage activation by sCD163 and sMR in patients with non-cirrhotic portal hypertension (PVT and IPH) and compare this to patients with cirrhotic portal hypertension with and without PVT and in healthy controls. Here, CD163 is linked to liver disorder.